How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about daratumumab

Marketing authorisation indication

2.1 Daratumumab (Darzalex, Janssen) in combination with lenalidomide and dexamethasone is indicated for 'the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant'.

Dosage in the marketing authorisation

2.2 The dosage schedule for both injection and infusion formulations are available in the summary of product characteristics for daratumumab.

Price

2.3 The list prices for daratumumab (excluding VAT; BNF online, accessed January 2023) are:

  • £4,320 per 1,800 mg/15 ml solution for injection vial

  • £360 per 100 mg/5 ml concentrate for solution for infusion vial

  • £1,440 per 400 mg/20 ml concentrate for solution for infusion vial.

2.4 The company has a commercial arrangement. This makes daratumumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.5 The list price for lenalidomide is £3,057.60 per 21‑pack of 25 mg capsules (excluding VAT; BNF online, accessed January 2023). List prices for different doses are available on the BNF webpage for medicinal forms of lenolidomide. There is a discount for lenalidomide agreed with the Commercial Medicines Unit. The prices agreed through the framework are commercial in confidence.

2.6 The list price of dexamethasone is £19.62 per 50‑pack of 4 mg capsules (excluding VAT; electronic market information tool (eMIT) online, accessed January 2023). List prices for different doses are available on the BNF webpage for medicinal forms of dexamethasone. Costs may vary in different settings because of negotiated procurement discounts.